X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA AUROBINDO PHARMA SHASUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 123.9 14.3 864.9% View Chart
P/BV x 8.5 3.7 232.0% View Chart
Dividend Yield % 0.2 0.4 54.9%  

Financials

 SHASUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
AUROBINDO PHARMA
Mar-17
SHASUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs94895 10.5%   
Low Rs46622 7.3%   
Sales per share (Unadj.) Rs214.2254.6 84.1%  
Earnings per share (Unadj.) Rs5.339.3 13.6%  
Cash flow per share (Unadj.) Rs15.846.6 34.0%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %1.40.3 434.0%  
Book value per share (Unadj.) Rs53.3160.0 33.3%  
Shares outstanding (eoy) m56.62585.88 9.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 11.0%   
Avg P/E ratio x13.119.3 67.8%  
P/CF ratio (eoy) x4.416.3 27.1%  
Price / Book Value ratio x1.34.7 27.6%  
Dividend payout %18.76.4 294.4%   
Avg Mkt Cap Rs m3,958444,390 0.9%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m2,16417,678 12.2%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m12,127149,157 8.1%  
Other income Rs m2291,159 19.8%   
Total revenues Rs m12,356150,316 8.2%   
Gross profit Rs m1,00934,343 2.9%  
Depreciation Rs m5944,276 13.9%   
Interest Rs m415667 62.2%   
Profit before tax Rs m23030,558 0.8%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-737,597 -1.0%   
Profit after tax Rs m30223,012 1.3%  
Gross profit margin %8.323.0 36.1%  
Effective tax rate %-31.724.9 -127.4%   
Net profit margin %2.515.4 16.1%  
BALANCE SHEET DATA
Current assets Rs m6,88492,062 7.5%   
Current liabilities Rs m8,45666,223 12.8%   
Net working cap to sales %-13.017.3 -74.8%  
Current ratio x0.81.4 58.6%  
Inventory Days Days62106 58.2%  
Debtors Days Days10868 158.9%  
Net fixed assets Rs m4,97062,919 7.9%   
Share capital Rs m113586 19.3%   
"Free" reserves Rs m2,87593,133 3.1%   
Net worth Rs m3,02093,719 3.2%   
Long term debt Rs m1,8171,814 100.2%   
Total assets Rs m13,347162,494 8.2%  
Interest coverage x1.646.8 3.3%   
Debt to equity ratio x0.60 3,108.9%  
Sales to assets ratio x0.90.9 99.0%   
Return on assets %5.414.6 36.9%  
Return on equity %10.024.6 40.7%  
Return on capital %13.332.7 40.7%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84375,838 7.7%   
Fx outflow Rs m2,17330,224 7.2%   
Net fx Rs m3,66945,613 8.0%   
CASH FLOW
From Operations Rs m39832,786 1.2%  
From Investments Rs m-1,635-17,870 9.1%  
From Financial Activity Rs m1,309-19,153 -6.8%  
Net Cashflow Rs m71-4,239 -1.7%  

Share Holding

Indian Promoters % 39.2 54.1 72.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 8.0 45.3%  
FIIs % 17.6 27.7 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.2 388.2%  
Shareholders   20,750 69,601 29.8%  
Pledged promoter(s) holding % 12.3 8.6 143.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS